Thursday, March 29, 2018

BRIEF-‍Lexicon announces EMA acceptance of MAA for Sotagliflozin to treat adults with Type 1 Diabetes​

* ‍LEXICON PHARMACEUTICALS ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION (MAA) FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES​ Source text for Eikon: Further company coverage:
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)